期刊文献+

磷酸二酯酶4抑制剂Hemay005对角质形成细胞炎性因子产生的影响 被引量:1

Effects of Phosphodiesterase 4 Inhibitor Hemay005 on the Expression of Inflammatory Factors in Human Keratinocytes
下载PDF
导出
摘要 目的为了探讨磷酸二酯酶4抑制剂Hemay005对体外培养的角质形成细胞株HaCaT细胞炎性因子产生的影响。方法分别用重组人肿瘤坏死因子-α(rhTNF-α)、重组人干扰素-γ(rhIFN-γ)和312 nm窄波UVB诱导,采用MTT法检测Hemay005对HaCaT细胞增殖的影响,用ELISA法检测其对HaCaT细胞白细胞介素(IL)-8、sICAM-1和肿瘤坏死因子(TNF)-α产生的影响。结果 Hemay005对HaCaT细胞增殖及25μg/L rhTNF-α诱导的IL-8产生无明显影响,但能剂量依赖性地抑制1 000 U/mL rhIFN-γ诱导的HaCaT细胞产生sICAM-1和124.2 mJ/cm2窄波UVB照射引起的HaCaT细胞产生TNF-α。结论 Hemay005可通过抑制角质形成细胞炎症因子的表达发挥抗炎作用。 Objective To investigate effects of phosphodiesterase 4 inhibitor Hemay005 on the proliferation of keratinocytes and expression of inflammatory factors. Methods HaCaT keratinoeytes were induced by recombinant human TNF-α (rhTNF-α, recombinant human IFN-γ (rhIFN-γ) and 312 nm UVB, respectively. The proliferation of HaCaT cells were detected by MTF method, the production of IL-8, sICAM-1 and TNF-α in HaCaT cells were determined by ELISA. Results It showed that HemayO05 had no significant influence on the proliferation of HaCaT cells and the production of IL-8 induced by 25 ng/mL rhTNF-α, but it could inhibit the production of sICAM-1 induced by 1000 U/mL rhIFN-γand TNF-α stimulated by 124.2 mJ/cm^2 narrowband UVB in a dose-dependent manner. Conclusion Hemay005 might play the role of antipsoriasis by inhibiting the expression of inflammatory factors.
出处 《中国中西医结合皮肤性病学杂志》 CAS 2014年第1期9-12,共4页 Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine
关键词 磷酸二酯酶4抑制剂 白细胞介素-8 可溶性细胞间黏附分子-1 肿瘤坏死因子-α INTERLEUKIN-8 Soluble INTERCELLULAR adhesion MOLECULE-1 Tumor necrosis factor-α Phosphodiesterase 4 inhibitor Interleukin-8 Soluble intercellular adhesion molecule-1 Tumor necrosisfactor-α
  • 相关文献

参考文献11

  • 1Albanesi C,Scarponi C,Giustizieri ML,et al.Keratinocytes in inflammatory skin diseases[J].Curr Drug Targets Inflamm Allergy,2005,4:329-334.
  • 2Dastidar SG,Rajagopal D,Ray A.Therapeutic benefit of PDE4 inhibitors inflammatory disease[J].Curr Opin Investig Drug,2007,8:364-372.
  • 3Ryan C,Abramson A,Patel M,et al.Current investigational drugs in psoriasis[J].Expert Opin Investig Drug,2012,21:473-487.
  • 4Shutty B,West C,Pellerin M,et al.Apremilast as a treatment for psoriasis[J].Expert Opin Pharmaeother,2012,13:1761-1770.
  • 5Hanel KH,Cornelissen C,Lüscher B,et al.Cytokines and the skin barrier[J].Int J Mol Sci,2013,14:6720-6745.
  • 6常晓萍,陈宏.肿瘤坏死因子-α在相关皮肤病发病中的作用[J].中国中西医结合皮肤性病学杂志,2009,8(1):62-64. 被引量:4
  • 7Borska L,Fiala Z,Krejsek J,et al.Immunologic changes in TNF-alpha,sE-selectin,sP-selectin,sICAM-1,and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen[J].Pediatr Dermatol,2007,24:607-612.
  • 8黄莹雪,李新宇.磷酸二酯酶4抑制剂抗银屑病机制研究进展[J].国际皮肤性病学杂志,2011,37(3):140-143. 被引量:1
  • 9Burnouf C,Pruniaux MP.Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs[J].Curr Pharm Des,2002,8:1255-1296.
  • 10Castro A,Jerez MJ,Gil C,et al.Cyclic nucleotide phosphodiesterascs and their role in imnmnonmdulalory responses:advances in the development of specific phosphodiesterase inhibitors[J].Med Res Rev,2005,25:229-244.

二级参考文献39

  • 1丁政云,李鑫,王欣,赵保廷,高顺强,刘丽娟,蔡丽,徐素芹.肿瘤坏死因子α在扁平苔藓皮损中的表达[J].中华皮肤科杂志,2005,38(12):763-763. 被引量:11
  • 2张江林,谢红付,刘稚然,唐坤,施为,李宁.肿瘤坏死因子α2等位基因与系统性红斑狼疮相关性分析[J].临床皮肤科杂志,2006,35(3):135-136. 被引量:3
  • 3孙超渊,张莉,程克棣,杜冠华,朱平.磷酸二酯酶4研究进展[J].中国药理学通报,2006,22(10):1161-1167. 被引量:19
  • 4Harada D,Tsukumo Y,Takashima Y,et al.Effect of orally administered rolipram,a phosphodiesterase 4 inhibitor,on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.Eur J Pharmacol,2006,532(1-2):128-137.
  • 5B(a)umer W,Hoppmann J,Rundfeldt C,et al.Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.Inflamm Allergy Drug Targets,2007,6 (1):17-26.
  • 6Harada D,Takada C,Nosaka Y,et al.Effect of orally administered KF66490,a phosphodiesterase 4 inhibitor,on dermatitis in mouse models.Int Immunopharmacol,2009,9(1):55-62.
  • 7Nazarian R,Weinberg JM.AN-2728,a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis.Curr Opin Investig Drugs,2009,10(11):1236-1242.
  • 8Schafer PH,Parton A,Gandhi AK,et al.Apremilast,a cAMP phosphodiesterase-4 inhibitor,demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.Br J Pharmacol,2010,159(4):842-855.
  • 9Gottlieb AB,Strober B,Krueger JG,et al.An open-label,single arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent,apremilast.Curr Med Res Opin,2008,24(5):1529-1538.
  • 10Nestle FO,Kaplan DH,Barker J.Psoriasis.N Engl J Med,2009,361(5):496-509.

共引文献4

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部